Epilepsy is one of the most common serious neurological disorders, affecting over 70 million people worldwide (1). Approximately 30% to 40% of patients with epilepsy (PWE) develop drug-resistant epilepsy (DRE) despite receiving appropriate anti-seizure medication (ASM) (2, 3). It is well documented that drug-resistant epilepsy is associated with an increased risk of mortality, injuries, psychosocial dysfunction, and poor quality of life (4–7). Thus, identifying clinically useful predictors of the occurrence of DRE in newly treated patients would have significant clinical benefits.
23
OCT
OCT
0